Last reviewed · How we verify

Nicotine Replacement Therapy

Ottawa Hospital Research Institute · FDA-approved active Small molecule

Nicotine replacement therapy delivers nicotine to the body through alternative routes (patches, gum, lozenges, nasal spray, or inhalers) to reduce withdrawal symptoms and cravings during smoking cessation.

Nicotine replacement therapy delivers nicotine to the body through non-combustible routes to reduce withdrawal symptoms and cravings during smoking cessation. Used for Smoking cessation aid, Reduction of cigarette consumption in smokers unwilling to quit abruptly.

At a glance

Generic nameNicotine Replacement Therapy
Also known asNicoderm CQ, NRT, Nicotine Lozenges, Nicogum 2mg Cipla pharmaceuticals, Nicotine Patch
SponsorOttawa Hospital Research Institute
Drug classNicotinic acetylcholine receptor agonist
TargetNicotinic acetylcholine receptors
ModalitySmall molecule
Therapeutic areaAddiction Medicine / Smoking Cessation
PhaseFDA-approved

Mechanism of action

NRT works by providing nicotine without the harmful combustion products of tobacco smoke, allowing smokers to gradually reduce their dependence on cigarettes. Nicotine binds to nicotinic acetylcholine receptors in the brain, satisfying the neurochemical basis of addiction while the patient works to break the behavioral habit. This approach separates nicotine delivery from the reinforcing effects of smoking itself, facilitating gradual dose reduction and eventual cessation.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: